Plimoth Trust Co. LLC bought a new stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 5,645 shares of the company's stock, valued at approximately $486,000.
Other institutional investors and hedge funds have also bought and sold shares of the company. Xponance Inc. increased its stake in Novo Nordisk A/S by 27.6% during the 2nd quarter. Xponance Inc. now owns 2,665 shares of the company's stock valued at $380,000 after purchasing an additional 576 shares in the last quarter. AQR Capital Management LLC grew its holdings in shares of Novo Nordisk A/S by 110.5% during the second quarter. AQR Capital Management LLC now owns 17,164 shares of the company's stock valued at $2,450,000 after buying an additional 9,012 shares during the last quarter. The Manufacturers Life Insurance Company raised its stake in Novo Nordisk A/S by 2.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 131,876 shares of the company's stock worth $18,824,000 after acquiring an additional 2,817 shares during the last quarter. Sunbelt Securities Inc. lifted its position in Novo Nordisk A/S by 1.3% during the 2nd quarter. Sunbelt Securities Inc. now owns 10,752 shares of the company's stock worth $1,535,000 after acquiring an additional 138 shares during the period. Finally, EP Wealth Advisors LLC grew its stake in Novo Nordisk A/S by 37.6% during the 2nd quarter. EP Wealth Advisors LLC now owns 65,844 shares of the company's stock valued at $9,399,000 after purchasing an additional 17,982 shares during the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Several research analysts have recently issued reports on the company. StockNews.com cut Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a research note on Sunday, December 29th. BNP Paribas raised shares of Novo Nordisk A/S to a "strong-buy" rating in a report on Monday, December 2nd. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a report on Monday, January 6th. UBS Group raised shares of Novo Nordisk A/S from a "sell" rating to a "buy" rating in a report on Wednesday, January 8th. Finally, BMO Capital Markets reduced their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating for the company in a research note on Monday, December 23rd. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Novo Nordisk A/S presently has an average rating of "Buy" and a consensus price target of $145.25.
Get Our Latest Analysis on NVO
Novo Nordisk A/S Price Performance
Shares of Novo Nordisk A/S stock traded down $0.98 during trading hours on Friday, reaching $84.36. The stock had a trading volume of 6,542,055 shares, compared to its average volume of 8,870,016. The stock's 50 day moving average is $93.56 and its 200 day moving average is $113.22. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. Novo Nordisk A/S has a twelve month low of $78.17 and a twelve month high of $148.15. The firm has a market capitalization of $378.56 billion, a PE ratio of 27.30, a PEG ratio of 0.92 and a beta of 0.45.
Novo Nordisk A/S Company Profile
(
Free Report)
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.
Featured Stories
![Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)](https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&Symbol=NVO)
Before you consider Novo Nordisk A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novo Nordisk A/S wasn't on the list.
While Novo Nordisk A/S currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.